Table 1 Demographic features, presentation, and outcome of patients with nodal PTCL, NOS with cytotoxic phenotype.
Features | n | % |
|---|---|---|
Gender | 54 | |
M | 39 | 72% |
F | 15 | 28% |
Age (years) | 54 | |
≤60 | 28 | 52% |
>60 | 26 | 48% |
Clinical stage | 49 | |
I | 3 | 6% |
II | 1 | 2% |
III | 7 | 14% |
IV | 38 | 78% |
Performance status | 41 | |
0-1 | 27 | 66% |
2-4 | 14 | 34% |
B symptoms | 46 | |
yes | 31 | 67% |
no | 15 | 33% |
LDH | 41 | |
increased | 32 | 78% |
normal | 9 | 22% |
IPI | 40 | |
0-2 | 15 | 38% |
3 | 12 | 30% |
4-5 | 13 | 33% |
PIT | 37 | |
0-2 | 22 | 59% |
3-4 | 15 | 41% |
Hemoglobin | 35 | |
≥10 g/dL | 26 | 74% |
<10 g/dL | 9 | 26% |
Platelets | 34 | |
≥100 G/L | 23 | 68% |
<100 G/L | 11 | 32% |
Extranodal site(s) | 46 | |
≥ 1 site(s) | 40 | 87% |
Medical history | 51 | |
B-cell malignancy | 10 | 20% |
Other neoplasms | 3 | 6% |
Immune disorders | 4 | 8% |
Not significant | 34 | 67% |
Treatment | 48 | |
CHOP-like therapy | 38 | 79% |
others | 6 | 13% |
absence of treatment | 4 | 8% |
HSCT | 48 | |
autologous | 7 | |
allogeneic | 8* | |
Outcome | 50 | |
Alive | 15 | 30% |
Complete Remission | 9 | 18% |
Died | 35 | 70% |
Lymphoma and/or infection and/or treatment-related toxicity | 31 | 62% |
2 yr OS | 44% | |
5 yr OS | 22% | |
median OS | 12,7 months | |
